Article
Co-Expression of Human Adenosine Deaminase and Multidrug Resistance Using a Bicistronic Retroviral Vector
10 Feb 1998
Abstract excerpt
Current gene therapy protocols designed to treat adenosine deaminase (ADA) deficiency and other metabolic disorders suffer from low-efficiency delivery to target cells and a lack of long-term stability in expression of the therapeutic proteins. These problems may be resolved by use of an in vivo dominant selection. The multidrug transporter (MDR1) has been suggested as a useful selective marker for gene therapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
